Invasive fungal infections in solid organ transplant recipients

Future Microbiology

Volumn 7, Issue 5, 2012, Pages 639-655

  Shoham, Shmuel ^a   Marr, Kieren A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antifungal; aspergillosis; candidiasis; cryptococcosis; fungal; galactomannan; kidney transplant; liver transplant; lung transplant; transplant

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIBIOTIC AGENT; CASPOFUNGIN; CORTICOSTEROID; ECHINOCANDIN; ENDO 1,3 BETA GLUCANASE; FLUCONAZOLE; FLUCYTOSINE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIBIOTIC PROPHYLAXIS; ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; BILOMA; BLADDER CATHETERIZATION; BLASTOMYCES DERMATITIDIS; BLASTOMYCOSIS; BONE MARROW TOXICITY; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CANDIDEMIA; CANDIDIASIS; CANDIDURIA; CENTRAL NERVOUS SYSTEM INFECTION; CENTRAL VENOUS CATHETER; CEREBROSPINAL FLUID PRESSURE; CHOLEDOCHOJEJUNOSTOMY; COCCIDIOIDES IMMITIS; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; DERMATITIS; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG MEGADOSE; ELECTROLYTE DISTURBANCE; ENVIRONMENTAL EXPOSURE; FUNGAL COLONIZATION; FUNGUS TRANSMISSION; FUSARIUM; GRAFT RECIPIENT; HEART TRANSPLANTATION; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOGLOBULIN DEFICIENCY; INFECTION RISK; INOTROPISM; INTENSIVE CARE UNIT; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; KIDNEY TRANSPLANTATION; LIVER TOXICITY; LIVER TRANSPLANTATION; LUNG INFECTION; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PICHIA GUILLIERMONDII; POLYMERASE CHAIN REACTION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; REVIEW; SCEDOSPORIUM; SCEDOSPORIUM APIOSPERMUM; SIDE EFFECT; SYSTEMIC MYCOSIS; UNSPECIFIED SIDE EFFECT;

ASPERGILLOSIS; CANDIDIASIS; CRYPTOCOCCOSIS; FUNGEMIA; HUMANS; IMMUNOCOMPROMISED HOST; TRANSPLANTS;

EID: 84860869128     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.12.28     Document Type: Review

References (150)

1. Pappas PG, Alexander BD, Andes DR et al. Invasive fungal infections among organ transplant recipients: results of the Transplant- Associated Infection Surveillance Network (TRANSNET). Clin. Infect. Dis. 50(8), 1101-1111 (2010).
2. Neofytos D, Fishman JA, Horn D et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transplant. Infect. Dis. 12(3), 220-229 (2010).
3. Park BJ, Pappas PG, Wannemuehler KA et al. Invasive non-aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg. Infect. Dis. 17(10), 1855-1864 (2011).
4. Fishman JA. Infection in solid-organ transplant recipients. N. Engl. J. Med. 357(25), 2601-2614 (2007). (Pubitemid 350294226)
5. Ison MG, Hager J, Blumberg E et al. Donor-derived disease transmission events in the United States: data reviewed by the OPTN/UNOS disease transmission advisory committee. Am. J. Transplant. 9(8), 1929-1935 (2009)
6. van der Vliet JA, Tidow G, Kootstra G et al. Transplantation of contaminated organs. Br. J. Surg. 67(8), 596-598 (1980). (Pubitemid 10056814)
7. Wright PW, Pappagianis D, Wilson M et al. Donor-related coccidioidomycosis in organ transplant recipients. Clin. Infect. Dis. 37(9), 1265-1269 (2003). (Pubitemid 37372519)
8. Wong SY, Allen DM. Transmission of disseminated histoplasmosis via cadaveric renal transplantation: case report. Clin. Infect. Dis. 14(1), 232-234 (1992).
9. Mueller NJ, Weisser M, Fehr T et al. Donor-derived aspergillosis from use of a solid organ recipient as a multiorgan donor. Transplant. Infect. Dis. 12(1), 54-59 (2010).
10. Miller MB, Hendren R, Gilligan PH. Posttransplantation disseminated coccidioidomycosis acquired from donor lungs. J. Clin. Microbiol. 42(5), 2347-2349 (2004). (Pubitemid 38637883)
11. Martin-Davila P, Fortun J, Lopez-Velez R et al. Transmission of tropical and geographically restricted infections during solid-organ transplantation. Clin. Microbiol. Rev. 21(1), 60-96 (2008). (Pubitemid 351160010)
12. Limaye AP, Connolly PA, Sagar M et al. Transmission of histoplasma capsulatum by organ transplantation. N. Engl. J. Med. 343(16), 1163-1166 (2000).
13. Keating MR, Guerrero MA, Daly RC, Walker RC, Davies SF. Transmission of invasive aspergillosis from a subclinically infected donor to three different organ transplant recipients. Chest 109(4), 1119-1124 (1996). (Pubitemid 26113667)
14. Kanj SS, Welty-Wolf K, Madden J et al. Fungal infections in lung and heart-lung transplant recipients. Report of 9 cases and review of the literature. Med. (Baltimore) 75(3), 142-156 (1996). (Pubitemid 26159211)
15. Grossi PA, Fishman JA. Donor-derived infections in solid organ transplant recipients. Am. J. Transplant. 9(Suppl. 4), S19-S26 (2009).
16. Fischer SA, Avery RK. Screening of donor and recipient prior to solid organ transplantation. Am. J. Transplant. 9(Suppl. 4), S7-S18 (2009).
17. Calvino J, Romero R, Pintos E et al. Renal artery rupture secondary to pretransplantation Candida contamination of the graft in two different recipients. Am. J. Kidney Dis. 33(1), E3 (1999).
18. Baddley JW, Schain DC, Gupte AA et al. Transmission of Cryptococcus neoformans by organ transplantation. Clin. Infect. Dis. 52(4), E94-E98 (2011).
19. Mattner F, Kola A, Fischer S et al. Impact of bacterial and fungal donor organ contamination in lung, heart-lung, heart and liver transplantation. Infection 36(3), 207-212 (2008).
20. Van Hal SJ, Marriott DJ, Chen SC et al. Candidemia following solid organ transplantation in the era of antifungal prophylaxis: the Australian experience. Transplant. Infect. Dis. 11(2), 122-127 (2009).
21. Lockhart SR, Wagner D, Iqbal N et al. Comparison of in vitro susceptibility characteristics of Candida species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: Transplant- Associated Infections Surveillance Network (TRANSNET), 2001 to 2006. J. Clin. Microbiol. 49(7), 2404-2410 (2011).
22. Tavanti A, Lupetti A, Ghelardi E et al. Molecular monitoring of Candida albicans infections in liver transplant recipients. Eur. J. Clin. Microbiol. Infect. Dis. 20(8), 544-553 (2001). (Pubitemid 32905530)
23. Bendel CM, Wiesner SM, Garni RM, Cebelinski E, Wells CL. Cecal colonization and systemic spread of Candida albicans in mice treated with antibiotics and dexamethasone. Pediatr. Res. 51(3), 290-295 (2002). (Pubitemid 34174963)
24. Charles PE, Dalle F, Aube H et al. Candida spp. colonization significance in critically ill medical patients: a prospective study. Intensive Care Med. 31(3), 393-400 (2005).
25. Bartholomew GA, Rodu B, Bell DS. Oral candidiasis in patients with diabetes mellitus: a thorough analysis. Diabetes Care 10(5), 607-612 (1987). (Pubitemid 17158934)
26. Shoham S, Marwaha S. Invasive fungal infections in the ICU. J. Intensive Care Med. 25(2), 78-92 (2010).
27. Nieto-Rodriguez JA, Kusne S, Manez R et al. Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients. Ann. Surg. 223(1), 70-76 (1996).
28. Patel R, Portela D, Badley AD et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 62(7), 926-934 (1996). (Pubitemid 26360353)
29. Husain S, Tollemar J, Dominguez EA et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 75(12), 2023-2029 (2003). (Pubitemid 36793286)
30. Alexander J, Limaye AP, Ko CW, Bronner MP, Kowdley KV. Association of hepatic iron overload with invasive fungal infection in liver transplant recipients. Liver Transplant. 12(12), 1799-1804 (2006). (Pubitemid 44911806)
31. Pappas PG, Silveira FP. Candida in solid organ transplant recipients. Am. J. Transplant. 9(Suppl. 4), S173-S179 (2009).
32. Kusne S, Furukawa H, Abu-Elmagd K et al. Infectious complications after small bowel transplantation in adults: an update. Transplant. Proc. 28(5), 2761-2762 (1996). (Pubitemid 26339485)
33. Guaraldi G, Cocchi S, Codeluppi M et al. Outcome, incidence, and timing of infectious complications in small bowel and multivisceral organ transplantation patients. Transplantation 80(12), 1742-1748 (2005). (Pubitemid 43054000)
34. Battaglia M, Ditonno P, Selvaggio O et al. Kidney transplants from infected donors: our experience. Transplant. Proc. 36(3), 491-492 (2004). (Pubitemid 38534297)
35. Albano L, Bretagne S, Mamzer-Bruneel MF et al. Evidence that graft-site candidiasis after kidney transplantation is acquired during organ recovery: a multicenter study in France. Clin. Infect. Dis. 48(2), 194-202 (2009).
36. Mai H, Champion L, Ouali N et al. Candida albicans arteritis transmitted by conservative liquid after renal transplantation: a report of four cases and review of the literature. Transplantation 82(9), 1163-1167 (2006). (Pubitemid 44748018)
37. Gladdy RA, Richardson SE, Davies HD, Superina RA. Candida infection in pediatric liver transplant recipients. Liver Transplant. Surg. 5(1), 16-24 (1999). (Pubitemid 29037349)
38. Florescu DF, Islam KM, Grant W et al. Incidence and outcome of fungal infections in pediatric small bowel transplant recipients. Transplant. Infect. Dis. 12(6), 497-504 (2010).
39. Reid GE, Grim SA, Sankary H, Benedetti E, Oberholzer J, Clark NM. Early intraabdominal infections associated with orthotopic liver transplantation. Transplantation 87(11), 1706-1711 (2009).
40. Said A, Safdar N, Lucey MR et al. Infected bilomas in liver transplant recipients, incidence, risk factors and implications for prevention. Am. J. Transplant. 4(4), 574-582 (2004). (Pubitemid 38523580)
41. Safdar N, Said A, Lucey MR et al. Infected bilomas in liver transplant recipients: clinical features, optimal management, and risk factors for mortality. Clin. Infect. Dis. 39(4), 517-525 (2004). (Pubitemid 39120927)
42. Nucci M, Anaissie E, Betts RF et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin. Infect. Dis. 51(3), 295-303 (2010).
43. Berenguer J, Buck M, Witebsky F, Stock F, Pizzo PA, Walsh TJ. Lysis-centrifugation blood cultures in the detection of tissueproven invasive candidiasis. Disseminated versus single-organ infection. Diagn. Microbiol. Infect. Dis. 17(2), 103-109 (1993). (Pubitemid 23294544)
44. Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J. Clin. Microbiol. 49(2), 665-670 (2011).
45. Ostrosky-Zeichner L. Invasive mycoses: diagnostic challenges. Am. J. Med. 125(Suppl. 1), S14-S24 (2012).
46. Mennink-Kersten MA, Warris A, Verweij PE. 1,3-b-d-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N. Engl. J. Med. 354(26), 2834-2835 (2006). (Pubitemid 43974215)
47. Mennink-Kersten MA, Ruegebrink D, Verweij PE. Pseudomonas aeruginosa as a cause of 1,3-b-d-glucan assay reactivity. Clin. Infect. Dis. 46(12), 1930-1931 (2008).
48. Alexander BD, Smith PB, Davis RD, Perfect JR, Reller LB. The (1,3){b}-d-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation. J. Clin. Microbiol. 48(11), 4083-4088 (2010).
49. Chen J, Wang Y, Shen Z, Zhu Z, Song Y, Han R. Early diagnostic value of plasma PCT and BG assay for CRBSI after OLT. Transplant. Proc. 43(5), 1777-1779 (2011).
50. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48(5), 503-535 (2009).
51. Wahidi MM, Willner DA, Snyder LD, Hardison JL, Chia JY, Palmer SM. Diagnosis and outcome of early pleural space infection following lung transplantation. Chest 135(2), 484-491 (2009).
52. Kovats Z, Sutto Z, Murakozy G et al. Airway pathogens during the first year after lung transplantation: a single-center experience. Transplant. Proc. 43(4), 1290-1291 (2011).
53. Schaenman JM, Rosso F, Austin JM et al. Trends in invasive disease due to Candida species following heart and lung transplantation. Transplant. Infect. Dis. 11(2), 112-121 (2009).
54. Horvath J, Dummer S, Loyd J, Walker B, Merrill WH, Frist WH. Infection in the transplanted and native lung after single lung transplantation. Chest 104(3), 681-685 (1993). (Pubitemid 23268931)
55. Kubak BM. Fungal infection in lung transplantation. Transplant. Infect. Dis. 4(Suppl. 3), 24-31 (2002). (Pubitemid 34832433)
56. Hadjiliadis D, Howell DN, Davis RD et al. Anastomotic infections in lung transplant recipients. Ann. Transplant. 5(3), 13-19 (2000).
57. Delgado J, Calvo N, Gomis A et al. Candiduria in renal transplant recipients: incidence, clinical repercussion, and treatment indication. Transplant. Proc. 42(8), 2944-2946 (2010).
58. Safdar N, Slattery WR, Knasinski V et al. Predictors and outcomes of candiduria in renal transplant recipients. Clin. Infect. Dis. 40(10), 1413-1421 (2005). (Pubitemid 40628628)
59. Sobel JD, Bradshaw SK, Lipka CJ, Kartsonis NA. Caspofungin in the treatment of symptomatic candiduria. Clin. Infect. Dis. 44(5), E46-E49 (2007).
60. Ostrosky-Zeichner L, Pappas PG, Shoham S et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses 54(1), 46-51 (2011).
61. Hermsen ED, Zapapas MK, Maiefski M, Rupp ME, Freifeld AG, Kalil AC. Validation and comparison of clinical prediction rules for invasive candidiasis in intensive care unit patients: a matched case-control study. Crit. Care 15(4), R198 (2011).
62. Senn L, Eggimann P, Ksontini R et al. Caspofungin for prevention of intraabdominal candidiasis in high-risk surgical patients. Intensive Care Med. 35(5), 903-908 (2009).
63. Fortun J, Martin-Davila P, Montejo M et al. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation 87(3), 424-435 (2009).
64. Castroagudin JF, Ponton C, Bustamante M et al. Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients. Transplant. Proc. 37(9), 3965-3967 (2005). (Pubitemid 43015225)
65. Singhal S, Ellis RW, Jones SG et al. Targeted prophylaxis with amphotericin B lipid complex in liver transplantation. Liver Transplant. 6(5), 588-595 (2000).
66. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 131(10), 729-737 (1999). (Pubitemid 29531981)
67. Morgan J, Wannemuehler KA, Marr KA et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med. Mycol. 43(Suppl. 1), S49-S58 (2005). (Pubitemid 41038548)
68. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46(3), 327-360 (2008). (Pubitemid 351265310)
69. Panackal AA, Dahlman A, Keil KT et al. Outbreak of invasive aspergillosis among renal transplant recipients. Transplantation 75(7), 1050-1053 (2003). (Pubitemid 36438538)
70. Raviv Y, Kramer MR, Amital A, Rubinovitch B, Bishara J, Shitrit D. Outbreak of aspergillosis infections among lung transplant recipients. Transplant. Int. 20(2), 135-140 (2007). (Pubitemid 46121991)
71. Pegues CF, Daar ES, Murthy AR. The epidemiology of invasive pulmonary aspergillosis at a large teaching hospital. Infect. Control Hosp. Epidemiol. 22(6), 370-374 (2001). (Pubitemid 32777038)
72. Pegues DA, Lasker BA, Mcneil MM, Hamm PM, Lundal JL, Kubak BM. Cluster of cases of invasive aspergillosis in a transplant intensive care unit: evidence of person-to-person airborne transmission. Clin. Infect. Dis. 34(3), 412-416 (2002). (Pubitemid 34062247)
73. Gavalda J, Len O, San Juan R et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin. Infect. Dis. 41(1), 52-59 (2005). (Pubitemid 40863744)
74. Rosenhagen M, Feldhues R, Schmidt J, Hoppe-Tichy T, Geiss HK. A risk profile for invasive aspergillosis in liver transplant recipients. Infection 37(4), 313-319 (2009).
75. Singh N, Pruett TL, Houston S et al. Invasive aspergillosis in the recipients of liver retransplantation. Liver Transplant. 12(8), 1205-1209 (2006). (Pubitemid 44194587)
76. Fortun J, Martin-Davila P, Moreno S et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transplant. 8(11), 1065-1070 (2002). (Pubitemid 35363635)
77. Weigt SS, Elashoff RM, Huang C et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am. J. Transplant. 9(8), 1903-1911 (2009).
78. Goldfarb NS, Avery RK, Goormastic M et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation 71(2), 242-246 (2001). (Pubitemid 32126107)
79. Husni RN, Gordon SM, Longworth DL et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin. Infect. Dis. 26(3), 753-755 (1998). (Pubitemid 28155032)
80. Westney GE, Kesten S, De Hoyos A, Chapparro C, Winton T, Maurer JR. Aspergillus infection in single and double lung transplant recipients. Transplantation 61(6), 915-919 (1996). (Pubitemid 26107428)
81. Grossi P, Farina C, Fiocchi R, Dalla Gasperina D. Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Italian study group of fungal infections in thoracic organ transplant recipients. Transplantation 70(1), 112-116 (2000). (Pubitemid 30490761)
82. Ersoy A, Dizdar OS, Koc AO, Akalin H, Ener B. Aspergillus fumigatus spondylodiskitis in renal transplant patient: voriconazole experience. Exp. Clin. Transplant. 9(4), 265-269 (2011).
83. Taillandier J, Alemanni M, Cerrina J, Le Roy Ladurie F, Dartevelle P. Aspergillus osteomyelitis after heart-lung transplantation. J. Heart Lung Transplant. 16(4), 436-438 (1997). (Pubitemid 27199600)
84. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect. Dis. 5(10), 609-622 (2005). (Pubitemid 41383906)
85. Park YS, Seo JB, Lee YK et al. Radiological and clinical findings of pulmonary aspergillosis following solid organ transplant. Clin. Radiol. 63(6), 673-680 (2008).
86. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin. Infect. Dis. 42(10), 1417-1427 (2006).
87. Clancy CJ, Jaber RA, Leather HL et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J. Clin. Microbiol. 45(6), 1759-1765 (2007). (Pubitemid 46933903)
88. Luong ML, Clancy CJ, Vadnerkar A et al. Comparison of an aspergillus real-time polymerase chain reaction assay with galactomannan testing of bronchoalvelolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. Clin. Infect. Dis. 52(10), 1218-1226 (2011).
89. Pasqualotto AC, Xavier MO, Sanchez LB et al. Diagnosis of invasive aspergillosis in lung transplant recipients by detection of galactomannan in the bronchoalveolar lavage fluid. Transplantation 90(3), 306-311 (2010).
90. Husain S, Paterson DL, Studer SM et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 83(10), 1330-1336 (2007). (Pubitemid 46800308)
91. Husain S, Clancy CJ, Nguyen MH et al. Performance characteristics of the platelia Aspergillus enzyme immunoassay for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid. Clin. Vaccin. Immunol. 15(12), 1760-1763 (2008).
92. Boonsarngsuk V, Niyompattama A, Teosirimongkol C, Sriwanichrak K. False-positive serum and bronchoalveolar lavage Aspergillus galactomannan assays caused by different antibiotics. Scand. J. Infect. Dis. 42(6-7), 461-468 (2010).
93. Fortun J, Martin-Davila P, Alvarez ME et al. False-positive results of Aspergillus galactomannan antigenemia in liver transplant recipients. Transplantation 87(2), 256-260 (2009).
94. Cornet M, Fleury L, Maslo C, Bernard JF, Brucker G. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J. Hosp. Infect. 51(4), 288-296 (2002). (Pubitemid 38001879)
95. Baddley JW, Andes DR, Marr KA et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin. Infect. Dis. 50(12), 1559-1567 (2010).
96. Petrovic J, Ngai A, Bradshaw S et al. Efficacy and safety of caspofungin in solid organ transplant recipients. Transplant. Proc. 39(10), 3117-3120 (2007). (Pubitemid 350251504)
97. Alexander BD, Perfect JR, Daly JS et al. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation 86(6), 791-796 (2008).
98. Singh N, Limaye AP, Forrest G et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 81(3), 320-326 (2006). (Pubitemid 43255714)
99. Singh N, Husain S. Invasive aspergillosis in solid organ transplant recipients. Am. J. Transplant. 9(Suppl. 4), S180-S191 (2009).
100. Cadena J, Levine DJ, Angel LF et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. Am. J. Transplant. 9(9), 2085-2091 (2009).
101. Neoh CF, Snell GI, Kotsimbos T et al. Antifungal prophylaxis in lung transplantation - a world-wide survey. Am. J. Transplant. 11(2), 361-366 (2011).
102. Harris JR, Lockhart SR, Debess E et al. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin. Infect. Dis. 53(12), 1188-1195 (2011).
103. Saha DC, Goldman DL, Shao X et al. Serologic evidence for reactivation of cryptococcosis in solid-organ transplant recipients. Clin. Vaccin. Immunol. 14(12), 1550-1554 (2007).
104. Silveira FP, Husain S, Kwak EJ et al. Cryptococcosis in liver and kidney transplant recipients receiving anti-thymocyte globulin or alemtuzumab. Transplant. Infect. Dis. 9(1), 22-27 (2007).
105. Sun HY, Alexander BD, Lortholary O et al. Unrecognized pretransplant and donorderived cryptococcal disease in organ transplant recipients. Clin. Infect. Dis. 51(9), 1062-1069 (2010).
106. Singh N, Alexander BD, Lortholary O et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J. Infect. Dis. 195(5), 756-764 (2007).
107. Singh N, Alexander BD, Lortholary O et al. Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin. Infect. Dis. 46(2), e12-e18 (2008). (Pubitemid 351269182)
108. Davis JA, Horn DL, Marr KA, Fishman JA. Central nervous system involvement in cryptococcal infection in individuals after solid organ transplantation or with AIDS. Transplant. Infect. Dis. 11(5), 432-437 (2009).
109. Osawa R, Alexander BD, Lortholary O et al. Identifying predictors of central nervous system disease in solid organ transplant recipients with cryptococcosis. Transplantation 89(1), 69-74 (2010).
110. Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg. Infect. Dis. 7(3), 375-381 (2001).
111. Singh N, Lortholary O, Dromer F et al. Central nervous system cryptococcosis in solid organ transplant recipients: clinical relevance of abnormal neuroimaging findings. Transplantation 86(5), 647-651 (2008).
112. Wu G, Vilchez RA, Eidelman B, Fung J, Kormos R, Kusne S. Cryptococcal meningitis: an analysis among 5,521 consecutive organ transplant recipients. Transplant. Infect. Dis. 4(4), 183-188 (2002). (Pubitemid 36142803)
113. Shoham S, Cover C, Donegan N, Fulnecky E, Kumar P. Cryptococcus neoformans meningitis at 2 hospitals in Washington, D.C.: adherence of health care providers to published practice guidelines for the management of cryptococcal disease. Clin. Infect. Dis. 40(3), 477-479 (2005). (Pubitemid 40216519)
114. Singh N, Forrest G. Cryptococcosis in solid organ transplant recipients. Am. J. Transplant. 9(Suppl. 4), S192-S198 (2009).
115. Sun HY, Alexander BD, Lortholary O et al. Cutaneous cryptococcosis in solid organ transplant recipients. Med. Mycol. 48(6), 785-791 (2010).
116. Osawa R, Alexander BD, Forrest GN et al. Geographic differences in disease expression of cryptococcosis in solid organ transplant recipients in the United States. Ann. Transplant. 15(4), 77-83 (2010).
117. Sun HY, Singh N. Opportunistic infectionassociated immune reconstitution syndrome in transplant recipients. Clin. Infect. Dis. 53(2), 168-176 (2011).
118. Singh N, Lortholary O, Alexander BD et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin. Infect. Dis. 40(12), 1756-1761 (2005). (Pubitemid 40799944)
119. Singh N, Lortholary O, Alexander BD et al. Allograft loss in renal transplant recipients with Cryptococcus neoformans associated immune reconstitution syndrome. Transplantation 80(8), 1131-1133 (2005). (Pubitemid 41611940)
120. Singh N. How I treat cryptococcosis in organ transplant recipients. Transplantation 93(1), 17-21 (2012).
121. Baddley JW, Winthrop KL, Patkar NM et al. Geographic distribution of endemic fungal infections among older persons, United States. Emerg. Infect. Dis. 17(9), 1664-1669 (2011).
122. Vucicevic D, Carey EJ, Blair JE. Coccidioidomycosis in liver transplant recipients in an endemic area. Am. J. Transplant. 11(1), 111-119 (2011).
123. Braddy CM, Heilman RL, Blair JE. Coccidioidomycosis after renal transplantation in an endemic area. Am. J. Transplant. 6(2), 340-345 (2006). (Pubitemid 43382169)
124. Tripathy U, Yung GL, Kriett JM, Thistlethwaite PA, Kapelanski DP, Jamieson SW. Donor transfer of pulmonary coccidioidomycosis in lung transplantation. Ann. Thorac. Surg. 73(1), 306-308 (2002). (Pubitemid 34084592)
125. Proia L, Miller R. Endemic fungal infections in solid organ transplant recipients. Am. J. Transplant. 9(Suppl. 4), S199-S207 (2009).
126. Cuellar-Rodriguez J, Avery RK, Lard M et al. Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area. Clin. Infect. Dis. 49(5), 710-716 (2009).
127. Grim SA, Proia L, Miller R et al. A multicenter study of histoplasmosis and blastomycosis after solid organ transplantation. Transplant. Infect. Dis. 14(1), 17-23 (2011).
128. Gauthier GM, Safdar N, Klein BS, Andes DR. Blastomycosis in solid organ transplant recipients. Transplant. Infect. Dis. 9(4), 310-317 (2007). (Pubitemid 350059144)
129. Blair JE, Logan JL. Coccidioidomycosis in solid organ transplantation. Clin. Infect. Dis. 33(9), 1536-1544 (2001). (Pubitemid 34246148)
130. Hage CA, Ribes JA, Wengenack NL et al. A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin. Infect. Dis. 53(5), 448-454 (2011).
131. Wheat LJ, Freifeld AG, Kleiman MB et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 45(7), 807-825 (2007). (Pubitemid 47580372)
132. Jimenez C, Lumbreras C, Aguado JM et al. Successful treatment of mucor infection after liver or pancreas-kidney transplantation. Transplantation 73(3), 476-480 (2002). (Pubitemid 34174302)
133. Singh N, Gayowski T, Singh J, Yu VL. Invasive gastrointestinal zygomycosis in a liver transplant recipient: case report and review of zygomycosis in solid-organ transplant recipients. Clin. Infect. Dis. 20(3), 617-620 (1995).
134. Sun HY, Forrest G, Gupta KL et al. Rhino-orbital-cerebral zygomycosis in solid organ transplant recipients. Transplantation 90(1), 85-92 (2010).
135. Singh N, Aguado JM, Bonatti H et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J. Infect. Dis. 200(6), 1002-1011 (2009).
136. Sun HY, Aguado JM, Bonatti H et al. Pulmonary zygomycosis in solid organ transplant recipients in the current era. Am. J. Transplant. 9(9), 2166-2171 (2009).
137. Kubak BM, Huprikar SS. Emerging & rare fungal infections in solid organ transplant recipients. Am. J. Transplant. 9(Suppl. 4), S208-S226 (2009).
138. Perfect JR, Dismukes WE, Dromer F et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin. Infect. Dis. 50(3), 291-322 (2010).
139. Galgiani JN, Catanzaro A, Cloud GA et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses study group. Ann. Intern. Med. 133(9), 676-686 (2000).
140. Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44(1), 2-12 (2007). (Pubitemid 44968977)
141. Calvo E, Pastor FJ, Salas V, Mayayo E, Capilla J, Guarro J. Histopathology and antifungal treatment of experimental murine chromoblastomycosis caused by Cladophialophora carrionii. J. Antimicrob. Chemother. 67(3), 666-670 (2012).
142. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347(6), 408-415 (2002). (Pubitemid 34851833)
143. Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. Eur. J. Clin. Microbiol. Infect. Dis. 22(11), 651-655 (2003). (Pubitemid 37491617)
144. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 41(5), 634-653 (2005). (Pubitemid 41170352)
145. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356(24), 2472-2482 (2007). (Pubitemid 46919773)
146. Walsh TJ, Goutelle S, Jelliffe RW et al. Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients. Antimicrob. Agents Chemother. 54(8), 3451-3459 (2010).
147. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. 39(11), 1563-1571 (2004). (Pubitemid 39578526)
148. Winkler M, Pratschke J, Schulz U et al. Caspofungin for post solid organ transplant invasive fungal disease: results of a retrospective observational study. Transplant. Infect. Dis. 12(3), 230-237 (2010).
149. Brouwer AE, Rajanuwong A, Chierakul W et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 363(9423), 1764-1767 (2004). (Pubitemid 38698379)
150. Shoham S. Antifungal agents in adult transplant recipients. In: The AST Handbook of Transplant Infections. Kumar D, Humar A (Eds). Wiley-Blackwell, UK, 146-149 (2011).